The 237 antibody is a model murine monoclonal scFv, it recognizes a mutated glycopeptide expressed by an aggressive murine fi brosarcoma tumor cell line called Ag104a. The tumor-specifi c glycopeptide is generated as a result of a mutated chaperone protein Cosmc that when repaired, ablates the 237 neo-epitope. Ag104A cells express both the OTS8 transmembrane protein and a mutated Cosmcchaperone, resulting in naturally high levels of expression of the 237 epitope.
|CAT||Product Name||Target Species||Antibody Clone||Antibody Host||Receptor Construction||Vector Type||Targeting Cell Type||Inquiry & Datasheet|
|CAR-MZ103||Anti-237 epitope (237) h(CD28-CD3ζ) CAR, pCDCAR1||Human||237||Mouse||scFv-CD28-CD3ζ||Retroviral||T cell|
|CAT||Product Name||Clone||Promotor||Packaging System||Targeting Diseases||Inquiry & Datasheet|
|VP-CAR-LC803||Lenti-237 epitope CAR (scFv-CD28-CD3ζ, 237) Viral Particle||237||EF1a||Lentivirus|
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE